Showing results (261-270 of 366) with videos related to
Sort By:
Pageof 37
Journal of the National Cancer Institute|November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer modelsYuen-Li Chung, Helen Troy, Udai Banerji, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate CancerSusan Slovin, Syed Hussain, Fred Saad, et al.Bioorganic & Medicinal Chemistry Letters|March 7, 2007
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitorsMasahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, et al.BMC Research Notes|May 25, 2012
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopyLoreta M Rodrigues, Yuen-Li Chung, Nada M S Al Saffar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier statusZsofia Kote-Jarai, Richard D Williams, Nicola Cattini, et al.Bioorganic & Medicinal Chemistry|January 11, 2011
Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacementsJonathan M Large, Jane E Torr, Florence I Raynaud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignanciesUdai Banerji, Anne O'Donnell, Michelle Scurr, et al.Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.Bioorganic & Medicinal Chemistry|July 3, 2007
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitorsMasahiko Hayakawa, Ken-Ichi Kawaguchi, Hiroyuki Kaizawa, et al.Molecular Cancer Therapeutics|September 3, 2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivoAmir Faisal, Lynsey Vaughan, Vassilios Bavetsias, et al.Pageof 37